Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future
Top Cited Papers
Open Access
- 18 February 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Tumor Biology
- Vol. 37 (6), 7021-7031
- https://doi.org/10.1007/s13277-016-4911-7
Abstract
The field of plasma medicine has seen substantial advances over the last decade, with applications developed for bacterial sterilisation, wound healing and cancer treatment. Low temperature plasmas (LTPs) are particularly suited for medical purposes since they are operated in the laboratory at atmospheric pressure and room temperature, providing a rich source of reactive oxygen and nitrogen species (RONS). A great deal of research has been conducted into the role of reactive species in both the growth and treatment of cancer, where long-established radio- and chemo-therapies exploit their ability to induce potent cytopathic effects. In addition to producing a plethora of RONS, LTPs can also create strong electroporative fields. From an application perspective, it has been shown that LTPs can be applied precisely to a small target area. On this basis, LTPs have been proposed as a promising future strategy to accurately and effectively control and eradicate tumours. This review aims to evaluate the current state of the literature in the field of plasma oncology and highlight the potential for the use of LTPs in combination therapy. We also present novel data on the effect of LTPs on cancer stem cells, and speculatively outline how LTPs could circumvent treatment resistance encountered with existing therapeutics.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/H003797/1, EP/K018388/1)
- Wellcome Trust (097829/Z/11/A)
- Yorkshire Cancer Research (YCR - Y257PA, YCR - Y257PA)
This publication has 120 references indexed in Scilit:
- Cold Atmospheric Plasma for Selectively Ablating Metastatic Breast Cancer CellsPLOS ONE, 2013
- Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric PlasmaPLOS ONE, 2013
- Effects of a Non Thermal Plasma Treatment Alone or in Combination with Gemcitabine in a MIA PaCa2-luc Orthotopic Pancreatic Carcinoma ModelPLOS ONE, 2012
- Fabrication of gold nanoparticles for targeted therapy in pancreatic cancerAdvanced Drug Delivery Reviews, 2010
- Association of reactive oxygen species levels and radioresistance in cancer stem cellsNature, 2009
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaClinical Cancer Research, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002